Canada authorises compulsory licences for COVID-19 shortfalls
27-03-2020
Pharma industry challenges Canada’s drug pricing plan
09-09-2019
Fabio Berti / Shutterstock.com
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Innovative Medicines Canada, drug pricing, Canadian government, generics, Patented Medicine Prices Review Board, Life Sciences Ontario
